Galcanezumab: First Global Approval
@article{Lamb2018GalcanezumabFG, title={Galcanezumab: First Global Approval}, author={Yvette N. Lamb}, journal={Drugs}, year={2018}, volume={78}, pages={1769-1775} }
Galcanezumab-gnlm (Emgality™; Eli Lilly and Company), hereafter galcanezumab, is a humanized monoclonal antibody against the calcitonin gene-related peptide (CGRP) ligand. A potent vasodilator, CGRP is implicated in nociceptive transmission and migraine pathogenesis. In September 2018, the US FDA approved galcanezumab as a once-monthly subcutaneous injection for the preventive treatment of migraine in adults. In the same month, the EMA issued a positive opinion for galcanezumab for the… CONTINUE READING
Topics from this paper
12 Citations
Monoclonal antibodies for the prevention of migraine
- Medicine
- Expert opinion on biological therapy
- 2019
- 10
Safety and efficacy of galcanezumab in Taiwanese patients: a post-hoc analysis of phase 3 studies in episodic and chronic migraine
- Medicine
- Current medical research and opinion
- 2020
Galcanezumab for the Management of Migraine: A Systematic Review and Meta-Analysis of Randomized Placebo-Controlled Trials
- Medicine
- Cureus
- 2020
- PDF
Calcitonin Gene‐Related Peptide Modulators – The History and Renaissance of a New Migraine Drug Class
- Medicine
- Headache
- 2019
- 28
Functional impairment and disability among patients with migraine: evaluation of galcanezumab in a long-term, open-label study
- Medicine
- Quality of Life Research
- 2020
- PDF
Pharmacokinetics, Pharmacodynamics and Drug–Drug Interactions of New Anti-Migraine Drugs—Lasmiditan, Gepants, and Calcitonin-Gene-Related Peptide (CGRP) Receptor Monoclonal Antibodies
- Medicine
- Pharmaceutics
- 2020
- PDF
A prospective real-world analysis of erenumab in refractory chronic migraine
- Medicine
- The Journal of Headache and Pain
- 2020
- 9
Emerging treatments for cluster headache: hopes and disappointments
- Medicine
- Current opinion in neurology
- 2019
- 1
References
SHOWING 1-10 OF 28 REFERENCES
Effect of Different Doses of Galcanezumab vs Placebo for Episodic Migraine Prevention: A Randomized Clinical Trial
- Medicine
- JAMA neurology
- 2018
- 86
- PDF
Evaluation of Galcanezumab for the Prevention of Episodic Migraine: The EVOLVE-1 Randomized Clinical Trial
- Medicine
- JAMA neurology
- 2018
- 176
- Highly Influential
- PDF
Efficacy and safety of galcanezumab for the prevention of episodic migraine: Results of the EVOLVE-2 Phase 3 randomized controlled clinical trial
- Medicine
- Cephalalgia : an international journal of headache
- 2018
- 156
- Highly Influential
- PDF
Safety of galcanezumab in patients with episodic migraine: A randomized placebo-controlled dose-ranging Phase 2b study
- Medicine
- Cephalalgia : an international journal of headache
- 2018
- 38
Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of the CGRP Binding Monoclonal Antibody LY2951742 (Galcanezumab) in Healthy Volunteers
- Medicine
- Front. Pharmacol.
- 2017
- 38
- PDF
Translational Pharmacodynamics of Calcitonin Gene-Related Peptide Monoclonal Antibody LY2951742 in a Capsaicin-Induced Dermal Blood Flow Model
- Medicine
- The Journal of Pharmacology and Experimental Therapeutics
- 2015
- 39
- PDF
Safety and efficacy of LY2951742, a monoclonal antibody to calcitonin gene-related peptide, for the prevention of migraine: a phase 2, randomised, double-blind, placebo-controlled study
- Medicine
- The Lancet Neurology
- 2014
- 256
Development of a novel antibody to calcitonin gene-related peptide for the treatment of osteoarthritis-related pain.
- Medicine
- Osteoarthritis and cartilage
- 2014
- 63
- Highly Influential
EMGALITY (galcanezumab-gnlm) injection, for subcutaneous use: US prescribing information. 2018
- http://pi.lilly .com/. Accessed
- 2018